DALFAMPRIDINE

Other

Brand names: Dalfampridine

Oral

Mechanism of Action

12.1 Mechanism of action The mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated. Dalfampridine is a broad spectrum potassium channel blocker. In animal studies, dalfampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.

Indications

14 ).

FDA Warnings

5 WARNINGS AND PRECAUTIONS Dalfampridine extended-release tablets can cause seizures; the risk of seizures increases with increasing dalfampridine extended-release tablets doses; discontinue dalfampridine extended-release tablets and do not restart if a seizure occurs (5
The risk of seizures in patients with epileptiform activity on an EEG is unknown, and could be substantially higher than that observed in dalfampridine extended-release tablets clinical studies
Dalfampridine extended-release tablets are contraindicated in patients with a history of seizures [see Contraindications (4)]
Because patients with moderate to severe renal impairment (CrCl ≤50mL/min) would require a dose lower than 10 mg twice daily and no strength smaller than 10 mg is available, dalfampridine extended-release tablets are contraindicated in these patients [see Contraindications (4)]

Known Side Effects

9 documented side effects by frequency

Drug Not Working

>10%

Falls

1-10%

Fatigue

1-10%

Dizziness

1-10%

UTI

1-10%

Condition Worsened

0.1-1%

Weakness

0.1-1%

Insomnia

0.1-1%

Headache

0.1-1%

Community Discussions

No community discussions found for DALFAMPRIDINE yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral